Summary
Zoetis Inc. (ZTS) has filed its 2013 Annual Report on Form 10-K, detailing its performance and strategic positioning as a newly independent entity following its separation from Pfizer Inc. The company is a global leader in animal health, focusing on the discovery, development, manufacture, and commercialization of medicines and vaccines for both livestock and companion animals. In 2013, Zoetis reported total revenue of $4.56 billion, a 5% increase driven by operational growth across all segments, despite a 2% unfavorable impact from foreign exchange. The U.S. segment remains the largest contributor to revenue at 42%. The company emphasizes its strong R&D capabilities, with a focus on product lifecycle development, and its extensive sales and marketing infrastructure, which allows for deep customer relationships. Key product lines like ceftiofur, Revolution, and Draxxin contribute significantly to revenue. The report also highlights the company's financial restructuring, including a $3.65 billion senior notes offering, and outlines strategies for future growth centered on emerging markets, innovation, and customer engagement.
Financial Highlights
52 data points| Revenue | $4.56B |
| Cost of Revenue | $1.67B |
| Gross Profit | $2.89B |
| SG&A Expenses | $1.61B |
| Interest Expense | $113.00M |
| Net Income | $503.00M |
| EPS (Basic) | $1.01 |
| EPS (Diluted) | $1.01 |
| Shares Outstanding (Basic) | 500.00M |
| Shares Outstanding (Diluted) | 500.32M |
Key Highlights
- 1Zoetis reported total revenue of $4.56 billion for 2013, a 5% increase over 2012, driven by operational growth and partially offset by unfavorable foreign exchange impacts.
- 2The company completed its separation from Pfizer Inc. in 2013, marking its first full year as an independent public company, including an IPO and a $3.65 billion senior notes offering.
- 3Revenue is diversified across four geographic segments: U.S. (42%), Europe/Africa/Middle East (25%), Canada/Latin America (17%), and Asia/Pacific (16%).
- 4Livestock products accounted for 64% of revenue, while companion animal products made up 36%, reflecting the company's balanced market approach.
- 5Research and Development (R&D) expenses were $399 million in 2013, with a strategic focus on product lifecycle development to enhance existing product lines.
- 6The company's top ten product lines contributed 39% of revenue, indicating a diversified revenue stream rather than over-reliance on a single product.
- 7Zoetis maintains a strong competitive position, leveraging its direct sales force and technical expertise to build strong customer relationships within the animal health industry.